Overview A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia Status: Completed Trial end date: 2014-08-04 Target enrollment: Participant gender: Summary The purpose of this study is to investigate the safety and efficacy for 52-week dosing in hemodialysis patients with hyperphosphatemia. Phase: Phase 3 Details Lead Sponsor: Kissei Pharmaceutical Co., Ltd.